Actively Recruiting
Study of Alpelisib Treatment for Vascular Anomalies Driven by TIE2PIK3CA Pathway in Patients Aged 2 Months to 30 Years
Led by Children's Hospital of Philadelphia · Updated on 2026-10-19
61
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness and safety of Alpelisib in patients aged 2 months to 30 years with vascular anomalies driven by the PIK3CATIE-2TEK pathway. Alpelisib is approved by the FDA for certain breast cancers but is experimental for vascular anomalies in this study. The trial aims to assess how well Alpelisib works and its safety in this specific patient group. Participants will take oral Alpelisib daily in continuous 28-day cycles. Dosage varies by age those 18 years and older start at 125 mgday up to 250 mgday, while participants aged 6 to 17 years start at 50 mgday up to 200 mgday. A single dose reduction is allowed if side effects occur but clinical benefit remains. The treatment period lasts at least 2 years and can extend up to 3 years if there is a positive response. Regular clinic visits will occur, including up to 16 visits over the study duration. An optional part of the study includes blood collection for biomarker testing. During participation, individuals will attend study visits mostly lasting 30 minutes, with some visits up to 2 hours for completing questionnaires about their experience. They will take the study drug, have pictures taken, and keep drug diaries. Researchers will monitor responses using imaging, patient-reported outcomes, and clinical assessments over time. Safety is tracked through laboratory tests and clinical observations. The total participation time can be up to 3 years, with ongoing assessments at scheduled intervals.
CONDITIONS
Brief Title
24VA022; VATCH Alpelisib for TIE2/PIK3CA Pathway VAs
Research Team
C
CVAP Research Team
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here